Chicago Equity Partners LLC grew its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 6.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,240 shares of the medical research company’s stock after acquiring an additional 1,760 shares during the quarter. Chicago Equity Partners LLC’s holdings in PRA Health Sciences were worth $2,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares during the last quarter. Carroll Financial Associates Inc. boosted its holdings in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after buying an additional 790 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of PRA Health Sciences by 144.0% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock worth $115,000 after buying an additional 906 shares during the last quarter. CAPROCK Group Inc. purchased a new position in shares of PRA Health Sciences in the 2nd quarter worth about $208,000. Finally, Trustmark National Bank Trust Department purchased a new position in shares of PRA Health Sciences in the 2nd quarter worth about $225,000. 97.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PRA Health Sciences, Inc. (PRAH) opened at $79.06 on Friday. PRA Health Sciences, Inc. has a 52 week low of $51.16 and a 52 week high of $84.38. The stock has a market capitalization of $5,010.03, a PE ratio of 29.07, a P/E/G ratio of 1.37 and a beta of 0.43. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same period in the previous year, the business posted $0.64 EPS. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. equities analysts anticipate that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Friday, September 15th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. KeyCorp reissued a “buy” rating and issued a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Citigroup Inc. reissued a “buy” rating and issued a $93.00 price target (up from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Robert W. Baird boosted their price target on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $88.09.

WARNING: “Chicago Equity Partners LLC Has $2.30 Million Holdings in PRA Health Sciences, Inc. (PRAH)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/11/12/chicago-equity-partners-llc-has-2-30-million-holdings-in-pra-health-sciences-inc-prah.html.

In other news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $711,075,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Linda Baddour sold 100,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $7,485,000.00. The disclosure for this sale can be found here. Insiders sold a total of 10,000,000 shares of company stock worth $748,500,000 over the last 90 days. 2.10% of the stock is currently owned by company insiders.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.